Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
travel funds Freedom to explore high-risk concepts: three-year fully funded position Open, collaborative, interdisciplinary research environment Enabling framework in which to develop interdisciplinary
-
functional dimensions of human long non-coding RNAs (lncRNAs) in regulating human cardiovascular development, metabolism, function and disease. These new lncRNA functions include the broad interactions
-
cardiometabolic and mitochondrial biology. The Endogenous Peptides Laboratory, led by Dr. Lena Ho, is a leader in microprotein discovery, functional characterization and therapeutic development. The goal
-
composites. This multidisciplinary initiative, funded by the European Research Council (ERC PoC), aims to develop printable, high-performance, and environmentally conscious EMI shielding composites. Background
-
of the following projects: The molecular regulation of insulin secretion. In particular, the characterization of new (unpublished) transgenic models to study SENP1 (e.g. PMID: 38184650) The development of novel
-
tissue from the large brain bank at JHU to develop an integrated understanding of the disease. The ultimate goal of the BSL is to understand the biology of these diseases, to define novel biomarkers, and
-
team is seeking a highly motivated candidate with skills and understanding in antigen presentation utilizing bioinformatics tools to be applied to vaccine development utilizing viral vectors
-
, we educate tomorrow's physician/researchers, and we work with amazing partners, including other Harvard Medical School-affiliated hospitals. Located in Boston and the surrounding communities, Dana
-
the following things we are working on this may be the perfect opportunity: 1. Development of cell-free DNA (mutation and methylation), RNA, and exosomal-based liquid assays for early cancer detection
-
approaches and biochemical assays to target key proteins. This funded position is for a postdoctoral trainee interested in aiding the development of novel therapeutics for treating cancer or metabolic disease